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Background: Non-coding DNA in and around the human Amyloid Precursor Protein (APP) gene that is central to
Alzheimer’s disease (AD) shares little sequence similarity with that of appb in zebrafish. Identifying DNA domains
regulating expression of the gene in such situations becomes a challenge. Taking advantage of the zebrafish
system that allows rapid functional analyses of gene regulatory sequences, we previously showed that two
discontinuous DNA domains in zebrafish appb are important for expression of the gene in neurons: an enhancer in
intron 1 and sequences 28–31 kb upstream of the gene. Here we identify the putative transcription factor binding
sites responsible for this distal cis-acting regulation, and use that information to identify a regulatory region of the
human APP gene.
Results: Functional analyses of intron 1 enhancer mutations in enhancer-trap BACs expressed as transgenes in
zebrafish identified putative binding sites of two known transcription factor proteins, E4BP4/ NFIL3 and Forkhead, to
be required for expression of appb. A cluster of three E4BP4 sites at −31 kb is also shown to be essential for
neuron-specific expression, suggesting that the dependence of expression on upstream sequences is mediated by
these E4BP4 sites. E4BP4/ NFIL3 and XFD1 sites in the intron enhancer and E4BP4/ NFIL3 sites at −31 kb specifically
and efficiently bind the corresponding zebrafish proteins in vitro. These sites are statistically over-represented in
both the zebrafish appb and the human APP genes, although their locations are different. Remarkably, a cluster of
four E4BP4 sites in intron 4 of human APP exists in actively transcribing chromatin in a human neuroblastoma
cell-line, SHSY5Y, expressing APP as shown using chromatin immunoprecipitation (ChIP) experiments. Thus
although the two genes share little sequence conservation, they appear to share the same regulatory logic and are
regulated by a similar set of transcription factors.
Conclusion: The results suggest that the clock-regulated and immune system modulator transcription factor
E4BP4/ NFIL3 likely regulates the expression of both appb in zebrafish and APP in humans. It suggests potential
human APP gene regulatory pathways, not on the basis of comparing DNA primary sequences with zebrafish appb
but on the model of conservation of transcription factors.* Correspondence: pchatterjee@nccu.edu
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It is important to understand the regulation of the
Amyloid Precursor Protein (APP) gene expression be-
cause epidemiologic studies show that Alzheimer Dis-
ease (AD) is exquisitely sensitive to gene dosage [1], and
levels of APP expression including β-peptide levels cor-
relate with the severity and age-of-onset of AD [2]. The
severity and onset of AD is thus closely linked to expres-
sion of the APP gene. These observations suggest that
controlling APP gene expression is a possible route to
reducing the severity of AD. A pre-requisite for thera-
peutic manipulation of APP gene expression is a more
complete understanding of the mechanisms that regulate
APP expression in neurons. The APP gene promoter
does not contain a functional TATA box but instead has
long CpG islands and a strong initiator element (INR)
surrounding the major transcription start site [3]. While
transcriptional regulation of APP gene has been studied
extensively, most of that work has focused on the
proximal ~ 1500 bp sequences of the promoter [3-13],
and it is unclear to what extent APP gene is regulated by
promoter sequences alone. Like most other genes it is
likely that the APP promoter is modulated by distal
regulatory sequences. The non-coding DNA within and
surrounding the APP gene is not conserved in verte-
brates, and although ~700 bp of DNA immediately up-
stream of the start site is conserved in mammals, this
conservation does not extend to other vertebrates such
as Fugu or zebrafish [3,14]. Thus regulation of the gene
by cis-acting distal sequences remains poorly under-
stood. Although regulatory function can be conserved
across species without sequence similarity [15-19], iden-
tifying such sequences that control gene expression
under those circumstances is much more difficult.
We have previously shown that two discontinuous DNA
regions regulate neuron-specific appb gene expression in
zebrafish. One of these is an enhancer located within in-
tron 1; in the absence of this enhancer there is no expres-
sion of a BAC transgene that contained approximately
100 kb of 5’ sequences [14]. The second regulatory se-
quence mapped to a region located between approxi-
mately 28–31 kb 5’ of the transcription start site of the
zebrafish appb gene. Deletion of this element shifted the
expression pattern from being neuron-specific to noto-
chord-specific, which is the default pattern observed with
the basal promoter plus intron-enhancer combination.
Based on these observations, we proposed that the up-
stream element suppressed aberrant expression (in the
notochord) and activated appropriate expression in neu-
rons. Requirement of the upstream-enhancer for expres-
sion further suggested that zebrafish appb is regulated by
interaction between these distal regulatory sequences.
Here we identify the putative transcription factor bind-
ing sites that mediate activity of these regulatory regionsand use the information to study the regulation of the
human APP locus. Analysis of the expression of
enhancer-trap BACs containing mutated intron 1 enhan-
cers in zebrafish indicates that binding sites of at least
two known transcription factors are important for func-
tion. They are the clock-regulated and immune system
modulator transcription factor E4BP4/ NFIL3 and mem-
bers of the Forkhead gene family (XFD1). A search of
non-coding DNA in introns and the 50 kb sequence sur-
rounding the appb gene for additional binding sites
revealed a ~ 8-fold and~ 11-fold greater than statistical
frequency of E4BP4 and XFD1 sites, respectively.
Amongst these is a cluster of three E4BP4 sites at
−31 kb. These sites bound the E4BP4 DNA binding
domains, expressed in E. coli, efficiently and selectively
in vitro. Though comparison of zebrafish and human
APP did not reveal substantially conserved non-coding
sequences that could represent regulatory elements, we
hypothesized that gene expression may be conserved via
the use of the same transcription factors. Therefore, we
searched for E4BP4 binding sites in the human APP
locus. Remarkably, we found that putative E4BP4 sites
were also over-represented in the human APP locus,
though their locations differed from that seen in the zeb-
rafish appb. One such cluster of four E4BP4 binding
sites in the fourth intron of the human APP gene was
marked by a peak of acetylated histones in a human
neuroblastoma cell line that expresses APP. We propose
that E4BP4/ NFIL3 may regulate human APP expression
via binding to distal regulatory sequences.Methods
BAC clones
BACs CH211-192O20 and CH211-43O16 from a zebra-
fish library, designated here as BACs C and D respect-
ively, have been described [14]. The two BACs overlap
one another and contain different lengths of sequences
upstream of appb gene. Both were used in order to
have maximum upstream DNA, both closest to and
farthest from the appb transcription start site, in the
enhancer-trap BACs. This was necessitated by the ~110
kb packaging capacity of the phage P1 head used in
the generation of enhancer-trap BACs (see Figure 7 of
reference [14]).Generating enhancer-trap BACs
Progressive truncations from either end of BAC DNA,
purification and analyses of clone DNA from deletion li-
braries using Field Inversion Gel Electrophoresis (FIGE)
was performed using procedures described before [20-22].
Sequence of the newly created end was determined in each
case using primers from the Tn10 transposon end
remaining after the truncation.
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Injections of Qiagen tip-purified enhancer-trap BAC
DNA into zebrafish eggs and subsequent analyses of
EGFP expression in developing embryos using fluores-
cence microscopy were performed as reported earlier
[14]. To generate transgenic lines, enhancer-trap BAC
DNA with iTol2-end insertions were co-injected with
Tol2 transposase mRNA as described previously [23].
Mutagenesis of intron 1 enhancer in Enhancer-trap
transposon plasmid
Suitable PCR primers were used to amplify segments of
the 1 kb intron enhancer, and the amplified products
incorporated into the enhancer-trap Tn10 transposon
plasmid. Point mutations were engineered into PCR pri-
mers so that the amplified product contained mutations
in putative transcription factor binding sites that over-
lapped such as SOX5 and E4BP4. Thus to get mutations
in only SOX5 and not E4BP4, point mutations were
introduced. Changes to the putative binding sites were
first incorporated into the small plasmid containing the
enhancer-trap Tn10 which was then inserted into appb
BACs C and D, exactly as described previously to make
enhancer-trap BACs with the wild type sequence of the
intron enhancer [14].
Preparing zebrafish Forkhead and E4BP4/ NFIL3 proteins
Conserved DNA binding domains (DBD) of the zebra-
fish Forkhead and E4BP4 genes were amplified from
zebrafish genomic DNA using primers shown in
Additional file 1: Figure S1. Restriction sites were intro-
duced in-frame to the Forkhead and E4BP4 open read-
ing frames (ORFs) to facilitate cloning into the pET-30a
(+) expression vector. A six-histidine residue tag fused
to the N-terminal end of these proteins was used for
purification purposes as previously reported [24]. DBD
of Forkhead and E4BP4 were purified from bacteria as
previously described [25]. Electrophoretic Mobility Shift
Assays (EMSA) were performed exactly as described
earlier [25].
Chromatin Immunoprecipitation with H3K9Ac antibody
ChIPs, real-time PCR, and data analysis were performed
as described [26]. The anti-H3K9Ac antibody was pur-
chased from Abcam, Cambridge, MA. The control anti-
body anti-IgG was obtained from Millipore, Billerica,
MA. Human neuroblastoma SHSY5Y cells were propa-
gated in an undifferentiated state, cultured in DMEM
medium and 10% heat inactivated FBS. H3K9Ac ChIP
was performed on undifferentiated SHSY5Y cells. ChIP
primers were designed to span potential E4BP4 binding
sites, and are displayed in Additional file 2: Figure S2.
Primers used for detecting mRNA levels of E4BP4 inthe undifferentiated cell line SHSY5Y are displayed in
Additional file 3: Figure S3.
Identification of putative transcription factor (TF) binding
sites
The sequence in the 1 kb intron 1 enhancer of appb was
analyzed using the “MotifScanner” program, and the
results are shown in Additional file 2: Figure S2 of refer-
ence [14]. The putative TF binding sites with the highest
probability scores from that analysis are highlighted in
the intron enhancer sequence shown here in Additional
file 4: Figure S4. Mutational analyses of putative TF
binding sites within the intron 1 enhancer revealed that
E4BP4/ NFIL3 and XFD1 sites were required for func-
tion. Next, the genomic DNA sequence containing either
the zebrafish appb gene or the human APP gene, dis-
played in a Microsoft Word file, were scanned by the
“Find” function for the sequence representing the bind-
ing sites of E4BP4/ NFIL3 or XFD1. The reverse strand
binding sites for the two transcription factors were simi-
larly identified using the “Find” function on the
sequences complementary to the sites. The total of these
constituted the putative binding sites of each transcrip-
tion factor.
Sequence motif frequencies
Frequencies for random occurrence of putative binding
sites were calculated by raising ¼ (which represents the
probability of finding a specific nucleotide at any loca-
tion) to the total number of nucleotides in the consensus
binding site for the specific transcription factor. The fold
over-represented was deduced from the ratio of actual
occurrence at the genetic locus to what would be
expected if they occurred randomly.
Results
New technology for scanning the zebrafish appb gene
locus with enhancer traps using BACs was reported in an
earlier study [14], and is illustrated in Figure 1. The
enhancer-trap comprised of a basal promoter EGFP gene
flanked by 0.35 kb of sequence immediately upstream of
the appb transcription initiation site and~ 1 kb of DNA
containing the intron 1 enhancer of appb (shown sche-
matically in top panel of Figure 1). The enhancer-trap is
located in front of the loxP arrowhead in the Tn10 trans-
poson that is inserted randomly into BACs C and D over-
lapping the appb locus. Cre-mediated recombination
between this inserted enhancer-trap-loxP and the loxP en-
dogenous to the BAC generates libraries of appb-BAC
deletions in which the loxP end is brought progressively
closer to the lox511 end; while simultaneously placing the
enhancer-trap at the new loxP end. The set of enhancer-
trap appb-BACs is first characterized by sequencing the
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Figure 1 Scanning the appb genomic region of zebrafish by enhancer trapping using BACs represented schematically (summary of
results from reference [14]). The two BACs C and D used in this study overlap one another and contain different lengths of sequences
upstream of appb gene. They are shown schematically as the top two lines. The inverted triangle represents enhancer-trap in Tn10 transposon,
which is comprised of 0.35 kb of DNA immediately upstream of appb (UE), followed by EGFP gene with basal promoter, and ~1 kb intron 1
enhancer (IE). The entire enhancer-trap cassette is named BP-EGFP. The appb gene region in the BACs, with the thick blue arrow to represent the
total length of exons and introns of the gene, is drawn to scale and shown below it. Insertion of the enhancer-trap into the appb BAC DNA and
subsequent Cre recombination between the transposed loxP and the BAC-end loxP deletes the BAC DNA from that end and simultaneously
inserts the enhancer-trap (shown as BP-EGFP). The enhancer-trap is in front of loxP in the transposon and is retained in the BAC after Cre-
mediated loxP-loxP deletion. This end-truncation is represented by the bent line to illustrate the location of that transposon-end retained in the
BAC after the loxP-Cre deletion. The earlier study [14] found that appb BACs that had the enhancer-trap located close to the appb transcription
start site expressed EGFP fluorescence in neurons (e.g. BACs Δ74D, Δ70D, Δ94C, Δ92C Δ84C, Δ80C, Δ75C), while appb BACs that had the
enhancer-trap inserted further upstream beyond -31 kb of the appb gene expressed EGFP fluorescence in the notochord (e.g. BACs Δ72C, Δ52C,
Δ38C, Δ29C). The vertical blue dotted lines, separated by ~31 kb, mark these locations on the appb BACs. The names of BACs are indicated
adjacent to the pictures of EGFP expression in zebrafish neurons or the notochord.
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stream sequences both proximal and distal to appb tran-
scription start site in enhancer-trap BACs (see Methods,
and reference [14]).
Results from that previous study indicated that the en-
hancer in intron 1 can function specifically in non-neural
tissue such as the notochord, where endogenous appb is
not expressed, when used with promoter proximal ele-
ments within the +0.147 to −0.35 kb of sequence sur-
rounding the transcription start site of appb. Thus
expression in notochord was observed using either the
small enhancer-trap transposon plasmids containing only
the proximal promoter elements, or enhancer-trap appb-
BACs in which sequences −0.35 to −31 kb had been
deleted. However when additional 5’ sequences extending
till approximately −31 kb in the enhancer-trap appb-BACswere present, gene expression became exquisitely specific
to neurons (the vertical dashed blue lines in Figure 1 de-
marcate the end-points of deletions in the enhancer-trap
BACs that produce the two distinct expression patterns).
These results suggest that the intron enhancer works with
sequences in the −31 kb region to confer neuron-specific
gene expression. The results also appeared to suggest that
some type of transcription repression occurs by factors
binding to sequences between −28 and −31 kb to suppress
expression in the notochord, as deduced from the differ-
ent expression patterns of BACs Δ75C and Δ72C [14].
Simultaneous expression in the notochord and neural cells
was not observed in the same fish using BAC deletions
Δ74D through Δ75C (Summarized here in Figure 1 from
the data shown in Figure 7, Panels A-C of reference [14]).
We concluded that tissue-specific expression of the appb
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arate, somewhat distant regulatory domains to cooperate
in cis to confer tissue-specificity. The two domains of
regulation are the~ 1 kb of DNA within intron 1
(ZFISH7:9:29144733–29145740), and the region +0.147 to
−31 kb. As indicated in the earlier study, exclusion of the
~1 kb intron element produced no expression of GFP:
appb BACs with ~100 kb of 5’ sequences without the in-
tron 1 enhancer, i.e. BACs deleted from the wild type loxP
end of insert DNA with Tn-US that lacked the intron en-
hancer (Figures 1B, 1C, & 2 in reference [14]) failed toFigure 2 Panel A: Schematic representation of bio-informatically pred
(IE) within the enhancer-trap (taken from Additional file 2: Figure S2
Mutated enhancer-trap BACs used in this study: Mutations and deletions, re
the letters, were engineered into the intron enhancer (IE) in the small enha
SOX5, E4BP4, XFD1, OCT1, and GATA3. Each mutated enhancer-trap tra
enhancer-trap BACs indicated on the side of the corresponding mutation.
of the CT-repeat sequence in enhancer-trap (shown as dotted blue line), an
Because SOX5 and E4BP4 sites overlapped, only point mutations were intro
and point mutation in SOX5 and deletion of CT-repeat, shown in second ro
Δ17D Δ21D. Row 7 shows the wild type enhancer-trap with Δ94C, and Δ7
summarized in Table 1. The last enhancer-trap BAC in Panel B (row 8) has e
deleted from the lox511 end of BAC with the Tnlox511-iTol2kan to make th
lines on both ends of the BAC represent end-truncations by the transposo
preserved after either the loxP-loxP or lox511-lox511 deletions mediated byexpress GFP in any tissue. Absence of the region −0.35 to
−31 kb on the other hand led to expression in the in-
appropriate tissue, the notochord, as seen with BACs
Δ72C, Δ52C, Δ38C, and Δ29C.
Expression analyses of appb-BACs with mutated intron 1
enhancer: intact putative E4BP4 and XFD1 sites essential
for appb expression in zebrafish
Our previous study also reported a bio-informatic ana-
lysis of putative transcription factor binding sites within
the intron 1 enhancer sequence (Additional file 2: Figureicted transcription factor binding sites in the intron 1 enhancer
of reference[14]), highlighted by the colored letters. Panel B:
presented schematically with dotted lines of same color in place of
ncer-trap transposon plasmid at the sites marked by CT-repeat,
nsposon was inserted into appb BACs C and D to generate the
For example the blue dashed line in the first row indicates a deletion
d the BACs containing this mutation are Δ2C, Δ76C and Δ51D.
duced into the SOX5 site to obtain the plasmid with wild type E4BP4
w Panel B. Enhancer-trap BACs with these mutations are Δ5C Δ14C,
4D as representatives. The results of expressions of these BACs are
nhancer-trap deleted for CT-repeat, OCT1 and GATA3. This BAC is also
e germline transgenic zebrafish shown in Figure 3, Panel E. The bent
ns, and illustrate the location of the particular transposon end
Cre protein, respectively.
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scores in that list, such as SOX5, E4BP4, XFD1, OCT1
and GATA3, are shown schematically here in the intron
enhancer (IE) of the enhancer-trap transposon in
Figure 2A. Deletions from either end of the intron en-
hancer sequence and point mutations, to distinguish be-
tween overlapping sites, were made in these putative
transcription factor binding sites in the 1 kb intron en-
hancer of appb. Changes to the binding sites were first
incorporated into the small plasmid containing the
enhancer-trap Tn10 transposon (shown as the inverted
triangle in Figure 2A) which was then introduced into
appb BACs C and D, exactly as described previously to
make enhancer-trap BACs with the wild type sequence
of the intron enhancer. A schematic representation of all
enhancer-trap BACs containing mutated intron enhan-
cers that were used in this study is shown in Figure 2B.
Color-coded letters indicate the locations of the wild
type binding sites of transcription factors in intron en-
hancer (IE), while the dashed colored lines represent
deletions of that particular site. The identities of
mutated enhancer-trap BACs from each mutant intron
enhancer, used for expression in zebrafish in this study,
are indicated adjacent to the changes made. Mutant
enhancer-trap BACs chosen for expression had deletion-
ends within −31 kb of the appb transcription start site.
Most deletion-ends were within 10 kb, and some such as
Δ28D and Δ1D had deletion-ends <2 kb of the tran-
scription start site. The deletion-ends indicate locations
of the enhancer-trap in BACs, and are represented sche-
matically with the bent lines in Figures 1 and 2. The
lowest panel in Figure 2B shows a mutated enhancer-
trap BAC that was again deleted from the opposite end
by a lox511-iTol2kan transposon. Enhancer-trap BAC
DNAs were injected into zebrafish embryos for expres-
sion as transgenes. Locations of intron enhancer se-
quence-changes, and the PCR primers used to construct







Δ2C, Δ76C, Δ51D CT-ve
Δ5C, Δ14C, Δ17D, Δ21D CT-ve, SOX 5-ve
Δ17C, Δ9D, Δ14D CT-ve, SOX 5-ve, E4BP4-ve
Deletions from GATA3 end
Δ46C, Δ27D, Δ28D GATA3-ve
Δ3C, Δ4C, Δ1D GATA3-ve, OCT1-ve
Δ28C, Δ13D, Δ48D, Δ52D GATA3-ve, OCT1-ve, XFD1-ve
Mutations were engineered into the intron 1 enhancer (IE) of the enhancer-trap and
shown schematically in Panel B of Figure 2, and their expression patterns summarizFigure S4. A total of 18 mutated enhancer-trap trans-
poson-inserted BAC libraries were made, some with a
mixture of enhancer-traps containing the modified in-
tron enhancer in both orientations. Experiments inject-
ing DNA into zebrafish eggs were repeated at least four
times with BACs that expressed EGFP fluorescence in
neurons, and six times with BACs that did not express
EGFP. The results obtained with transient expressions
are summarized in Table 1 and indicate that the putative
binding sites for OCT1, GATA3, SOX5 and the CT-
repeat element are dispensable for appb expression in
zebrafish neurons. Clones such as Δ94C or Δ74D that
contain wild type intron enhancer (Figure 2B) generate
identical expression patterns as Δ5C with CT-repeat and
SOX5 deleted, or Δ1D with GATA3 and OCT1 deleted
(Figure 2B, Table 1). In contrast, DNA sequences that
contain E4BP4 or XFD1 sites are critical for expression
of appb in neurons of zebrafish. When mutated or
deleted, the resulting enhancer-trap BACs do not ex-
press either in neurons or the notochord. A FIGE of rep-
resentative larger than 75 kb appb BACs with mutated
intron 1 enhancers are shown in panel A of Figure 3.
The enhancer-traps in these BACs are located well
within 31 kb of the start site of transcription of appb.
A few of the BACs that expressed in neurons were fur-
ther retrofitted with iTol2-ends at the opposite lox511
end of BAC DNA for germline propagation, using the
transposon pTnlox511-iTol2kan as described recently
[23]. For example the BAC clone in lane 12 of Panel A,
Figure 3, (marked by yellow arrowhead), was truncated
from the lox511 end of BAC DNA using lox511-iTol2kan
transposon. Clone DNAs from the deletion/retrofitting li-
brary is shown in Panel B. Clone DNA from lane 11 in
Panel B (indicated by blue arrowhead) was introduced into
zebrafish eggs for germline propagation, and a F2 trans-
genic fish representative of this line is shown in Panel E. It
has an iTol2kan-EGFP-appb-BAC transgene with intron 1
enhancer deleted for GATA3, OCT1 and the CT-repeatppb BACs














inserted into appb BACs C and D. Structures of mutant enhancer-trap BACs
ed here in Table 1.
Figure 3 Panel A: FIGE analysis of enhancer-trap BACs with mutated intron 1 enhancer from different libraries. Panel B: FIGE analysis of
clone DNA from the library generated by inserting Tnlox511-iTol2kan at the lox511 end of the enhancer-trap BAC in lane 12, Panel A (marked by
yellow arrowhead). Panel C: EGFP fluorescence from transient expression in neurons (marked by the pink arrowheads) of zebrafish injected with
mutated but functional intron enhancer-trap BAC with intact upstream DNA, Panel D: EGFP expression in notochord (indicated with pink
arrowheads) from injecting enhancer trap BAC with mutated but functional intron enhancer and with 31 kb upstream DNA deleted (such as
clone in lane 21, panel B, red arrowhead) taken from the same library as the BAC used for Panel C. Panel E: EGFP fluorescence in neurons
(marked by the pink arrowhead) from a F2 transgenic zebrafish line obtained from the enhancer-trap BAC shown in lane 11 of Panel B (marked
by blue arrowhead). The mutated but functional intron enhancer used was deleted for GATA3, OCT1 and the CT-repeat element (clone shown
schematically in row 8, Panel B of Figure 2). Additional examples of germline transgenic fish with slightly smaller enhancer-trap BAC transgenes,
but containing the upstream ~31 kb sequence, are shown in Figure 6 panels A and B of reference [23]. The BAC vector DNA band from Not I
digestion is shown by the black arrowhead to the left of panels A and B. Lane 2, Panel B, contains the same DNA as lane 12, Panel A. Lanes 3–21
in panel B do not have this band because insertion of Tnlox511-iTol2kan at the lox511 end of BAC DNA and subsequent lox511-lox511 deletion
eliminates the Not I site at that end [23].
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in bottom panel of Figure 2B).
Distribution of E4BP4 and XFD1 sites in zebrafish appb
gene
A search of the genome database for additional E4BP4
and XFD1 sites within and 50 kb sequence surrounding
the zebrafish appb gene revealed that both these sites
are highly over-represented in the gene region, approxi-
mately 8-fold and 11-fold over statistical frequency, re-
spectively. These are shown schematically in Figure 4.
Amongst these is a cluster of three E4BP4 sites at
−31 kb. Locations of these sites are also tabulated in the
top panel of Additional file 5: Figure S5.
Sequence analysis of the new ends created by the
lox511-iTol2kan transposon in BAC DNAs in lanes 20
and 21, marked by the red arrowheads in Panel B, Figure 3,
indicated that the lox511-transposon had deleted the clus-
ter of three E4BP4 sites at −31 kb (Figure 4). When
injected into zebrafish embryos neither of these DNAs
expressed EGFP in neurons. Instead, expression patterns
were always in the notochord (Figure 3D), demonstratingthat the cluster of three E4BP4 sites at ~31 kb upstream
of appb, shown schematically in Figure 4, is necessary for
neuron-specific expression.
Conserved DNA binding protein domains of zebrafish
Forkhead and E4BP4 specifically recognize the XFD1 and
E4BP4 sites in intron enhancer and −31 kb of appb gene
in vitro
We next determined whether the proposed E4BP4 and
XFD1 sites in these regulatory regions bound the corre-
sponding zebrafish proteins. For this we expressed the
conserved DNA binding domains (DBD) of zebrafish
E4BP4 (147 aa) and Forkhead (154 aa) in E. coli. (shown
schematically in Additional file 1: Figure S1). The DNA
binding domains were partially purified under non-
denaturing conditions using the histidine tag, and used
in Electrophoretic Mobility Shift Assays (EMSA). As
EMSA probes we used probes e and f from intron 1 of
appb (Figure 5). Probe e, spanning site E11 in Figure 4,
formed a discrete nucleoprotein complex only with re-
combinant E4BP4-DBD (Figure 5A lanes 5–8) indicated
by the arrow, whereas probe f, spanning site X3 in Figure 4,
Figure 4 Location of E4BP4 (E, in green), and XFD1 (X, in red), sites in non-coding DNA within zebrafish appb and surrounding 50 kb
DNA. The green and red vertical lines above or below the horizontal line indicate sites in the forward and reverse strand of DNA, respectively.
The short yellow vertical bars indicate exons of appb. Stars mark the E4BP4 and XFD1 sites shown to specifically bind the DNA-binding domains
of zebrafish E4BP4 or Forkhead proteins respectively, by EMSA. The bent arrow indicates transcription start site of appb gene.
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lanes 1–4). Thus, the bio-informatically identified
sequences were indeed true E4BP4 and XFD1 binding
sites. Having determined the specificity of the probes we
further tested additional putative E4BP4 binding sites
(probes a-d, spanning sites E4 and E5, E6, E7, respect-
ively in Figure 4) that lie within the cluster of sites
located at −31 kb. All four new probes bound recombin-
ant E4BP4-DBD, though with different affinities
(Figure 5C). We conclude that both E4BP4 and XFD1
sites in intron 1, and the cluster of three sites at −31 kb
of appb bind zebrafish E4BP4 and Forkhead DBDs effi-
ciently and specifically in vitro.
E4BP4 binding sites in the human APP gene
Sequence comparisons of non-coding DNA within and
flanking the APP gene in humans and zebrafish did
not reveal appreciable conservation at the nucleotide
level. However, it was possible that the regulatory logic
was evolutionarily conserved between these distantly
related species. To determine if the regulatory infor-
mation obtained in zebrafish had implications for
human APP gene regulation, we first scored for E4BP4
binding sites in and around the human APP gene. We
noted a cluster of four putative E4BP4 binding sites in
intron 4 of human APP (Figure 6A). Locations of
these sites are also indicated in the bottom panel of
Additional file 5: Figure S5. As a first step towards de-
termining whether these sites were functionally import-
ant, we determined the histone modification state
around this cluster in a human neuroblastoma cellline, SHSY5Y, which expresses human APP mRNA.
Expression of E4BP4 mRNA was also confirmed in the
cell line using RT-PCR. We used antibodies directed
against histone H3 acetylated at lysine 9 (H3K9Ac) to
carry out chromatin immunoprecipitation (ChIP) assays;
the co-precipitated genomic DNA was queried by quantita-
tive PCR using primers that identified different parts of the
human APP gene (shown in Additional file 2: Figure S2).
We detected a modest peak of H3K9Ac activity centered
over the region with clustered E4BP4 sites (Figure 6B). As a
positive control we used ChIP primers located within the
promoter of the ubiquitously expressed IkappaBalpha
(IkBα) gene. We also assayed H3K9Ac at a region in intron
2 of human APP that has been previously shown to be
enriched for H3K27Ac (http://genome.ucsc.edu/cgi-bin/
hgTracks?position=chr21:27252862-27543138&hgsid=20363
7875&wgEncodeHaibTfbs.Peaks.vis=full), which is an-
other activation-associated histone modification. This re-
gion was highly modified with H3K9Ac. The fold
enrichment of H3K9Ac at this site and the intron 4 sites
was comparable (180-fold versus 120-fold, respectively,
(Figure 6B). We conclude that the E4BP4 site-containing
intron 4 region is epigenetically modified in these cells.
Discussion
Several previous reports have described elegant vector
systems and procedures to trap enhancers in the zebra-
fish [27-31]. The methods usually either insert the trap
directly into the chromosomes of the organism or test
sequences pre-selected based on cross-species conserva-
tion, for tissue-specific enhancer activity in Tol2 vectors.
Our approach using enhancer-trap BACs is not affected
Figure 5 The DNA binding domain common to members of zebrafish E4BP4 or Forkhead (Fkd) families were each expressed in E. coli,
partially purified under non-denaturing conditions, and tested for specific binding to their recognition sequences identified in and around
the zebrafish appb gene. Panel A: E4BP4 protein, indicated below each lane in μg, added to Fkd probe (f), lanes 1–3, or the E4BP4 probe (e),
lanes 4–8. Panel B: Fkd protein, indicated below each lane in μg, added to Fkd probe (f), lanes 1–4, or E4BP4 probe (e), lanes 5–7. Panel C:
E4BP4 protein binding to probes (a through f) spanning upstream E4BP4 sites (a-d), E4BP4 site in intron 1 enhancer (e), and Fkd site in intron
enhancer (f). E4BP4 protein used in each lane (μg) is indicated on right. Probes (b-d) correspond to cluster of three E4BP4 sites at −31 kb.
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cause insertion of the trap occurs in isolated pieces of
chromosomal DNA in BACs in the bacterial host
(advantages discussed in [32]). Our approach is also
likely to be free of biases, as there is no prior selection
of sequences to test for enhancer activity. The ability to
analyze multiple discontinuous DNA domains that act in
concert to regulate expression of a gene such as appb
appears a likely advantage of the enhancer-trap BAC
approach.
A large number of enhancer-trap BACs with deletions/
mutations in the intron 1 enhancer and the upstream
−31 kb region were analyzed in zebrafish, and putative
binding sites for E4BP4 and XFD1 were identified as
being critical for appb expression in neurons (Figures 2
and 3, Table 1). The two zebrafish transcription factor
proteins, expressed in E. coli, bound efficiently andselectively in vitro to their respective sites identified as
being essential for appb expression through mutational
analysis (Figure 5). These results were then used to ex-
plore whether a similar set of transcription factors could
also regulate expression of the human APP gene. We
noted that binding sites of E4BP4 and XFD1 were also sta-
tistically over-represented at the human APP gene locus
(Figure 6A). Chromatin immunoprecipitation (ChIP) ana-
lyses with H3K9Ac antibody of a cluster of four E4BP4
sites in intron 4 of human APP indicated that they were
epigenetically modified (Figure 6B). It suggests the sites
are functionally important in actively transcribing chro-
matin and are highly likely to serve a regulatory role.
SiRNA knock-down experiments to further demonstrate
that E4BP4 protein is actually involved in this regulation
will need to wait till protocols for efficient transfection of
the SHSY5Y neuroblastoma cells are devised.
Figure 6 (See legend on next page.)
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Figure 6 Panel A: Location of E4BP4 (E, green) and XFD1 (X, red) sites in non-coding DNA within the human APP gene and
surrounding 50 kb DNA. The green and red vertical lines above or below the horizontal line indicate sites in the forward and reverse strand of DNA,
respectively. The short yellow vertical bars indicate exons of APP. The first three exons are very close to one another near the transcription start site.
Stars indicate the E4BP4 sites marked by H3K9Ac in chromatin immunoprecipitation (ChIP) assays in a human cell-line SHSY5Y expressing APP gene.
The bent arrow indicates transcription start site of APP gene. The SHSY5Y cells were analyzed by ChIP using anti-H3K9Ac antibodies as described in
Methods. Y-axis represents the amount of material present in anti-H3K9Ac (Panel B) or non-specific IgG (Panel C) immunoprecipitates compared to
input chromatin used for the assay. Note the different scales for the two panels. Results shown are the average of three independent ChIP
experiments, each of which was assayed in duplicates. Error bars represent standard deviation between experiments. Amplification from IkBα served as
a positive control. The fold enrichment, over control IgG, of H3K9Ac activity at the APP intron 2 site (positive control) and the intron 4 sites are 180-fold
versus 120-fold, respectively, as indicated at the top of Panel 6B.
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expression of zebrafish appb
Expression of the BAC DNAs shown in lanes 20 and 21
of Figure 3B is not in neurons, quite unlike the other
clones from the same deletion series. Sequence analyses
of the new BAC end created by the lox511-iTol2kan
transposon insertion indicated that the cluster of three
E4BP4 sites at −31 kb was deleted in both these clones.
The dependence of appb expression in zebrafish neurons
on upstream sequences had also been mapped to that
same region in our previous study with deletions made by
the enhancer-trap transposon from the opposite loxP end
of BAC [14]. The conclusion that ~28 kb of upstream se-
quence is required for neuronal expression was derived
from the strikingly different patterns of expression of the
two enhancer-trap appb BACs Δ75C and Δ72C (see
Figure 7 in reference [14]), which had enhancer-trap loca-
tions at ~28 and >31 kb upstream, respectively, of the
appb transcription start site. That the three E4BP4 sites at
−31 kb are important for neuron-specific expression of
appb in zebrafish is thus re-confirmed here more directly.
The three E4BP4 sites at −31 kb also bind E4BP4-DBD ef-
ficiently and specifically in vitro (Figure 5).
Some members of Forkhead gene family expressed
exclusively in zebrafish notochord
An earlier study [33] indicates the Forkhead family of
transcription factors fkd1, fkd2 and fkd4 are expressed
during gastrulation in the zebrafish, with high levels of
fkd1 and fkd4 mRNA accumulating exclusively in the
notochord during somitogenesis. It suggests that fkd1,
fkd2 and fkd4 proteins are available only in the noto-
chord and thus could explain the expression of EGFP
exclusively in the notochord when the cluster of three
upstream E4BP4 sites at −31 kb are deleted in the
enhancer-trap appb-BACs (Figures 3, 4).
E4BP4 has repressor activity in addition to activation
properties, is intricately involved with the immune
system and its expression is clock-regulated
The transcription factor E4BP4, also known as NFIL3,
has been known to have both transcription activationand repression activities [34,35]. It serves in the Central
Nervous System (CNS) as an anti-apoptotic factor to
promote survival and growth of motor neurons [36]. As
NFIL3, it is also intricately linked with the immune
system, where it is required for protecting natural killer
(NK) T cells [37] and regulates IL-12 p40 in macro-
phages [38]. Strikingly, E4BP4/ NFIL3 has recently been
found to regulate the IL12b gene by acting as a repressor
from a distal enhancer 10 kb upstream of the gene using
the STAT3 pathway [39]. We believe these characteris-
tics of E4BP4/ NFIL3 are very relevant to our findings
because the importance of immunological and inflam-
matory processes in the pathogenesis and therapy of
Alzheimer's disease is well documented [40,41].
Results presented here indicate that the cluster of three
E4BP4 sites at −31 kb in the zebrafish gene (Figure 4) is
critical for neuron-specific expression of EGFP from pro-
moter elements of appb in conjunction with the intron
enhancer. Earlier reports of E4BP4 having transcription
repression activity [34-38], thus facilitates formulating the
following working hypothesis for appb gene regulation:
binding of both E4BP4 and Forkhead proteins to appb in-
tron 1 DNA is required for appb gene expression. The de-
pendence of neuronal appb expression on the three
E4BP4 sites at −31 kb could then be explained as follows:
with excess E4BP4, possibly from those bound to
sequences at −31 kb, Forkhead activity is suppressed, and
expression is specific to neurons. In the absence of these
upstream sequences, sequestered levels of E4BP4 are low,
and expression is in notochord.Possible model for appb gene regulation
We propose a novel interplay between Fkd and E4BP4/
NFIL3, either directly or indirectly through other proteins,
for restricting expression of appb to neurons. Although
required, the E4BP4 bound to the lone site in the minimal
intron 1 enhancer appears not to have enough repressive
function to prevent expression in the notochord. Thus in
the absence of the cluster of three E4BP4 sites at −31 kb,
expression is exclusive to the notochord because that is
where fkd1, fkd2 and fkd4 proteins are localized [33].
When the cluster of three E4BP4 sites is present,
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and expression is exclusive to neurons. The DNA region
28–31 kb upstream of appb is likely to have additional ac-
tivator sites that enhance neuron-specific expression.
For E4BP4/ NFIL3 and Forkhead to regulate appb
gene expression in the CNS, the proteins need to be
available in the zebrafish brain. Although evidence for
availability of these proteins in brain is lacking for zebra-
fish, expression has been reported for the Forkhead
protein in neurons of the mouse spinal cord [42], while
the E4BP4/ NFIL3 protein has been shown to be
expressed in the embryonic motor neurons of both rat
and chicken [36].Testing hypothesis for regulation of APP in humans
It is likely that APP gene regulation shares common fea-
tures in zebrafish and humans. However, the lack of
conservation in sequence of non-coding DNA around
the APP gene in these model vertebrates has been a di-
lemma [14]. We explored the hypothesis that conserva-
tion may be at the level of the transcription factors
involved. A search for E4BP4 and XFD1 sites in and
around the APP gene reveals a much greater than statis-
tical frequency of both these sites, just as in the case of
the zebrafish appb gene. There are 22 putative binding
sites for the human E4BP4/ NFIL3, about 6-fold above
statistical frequency, as shown in Figure 6A, with an
additional one in exon 23 (not shown). Although there
are only two sites with the XFD1 consensus sequence,
sites with 8 of 9 bases identical (consecutively) to the
consensus site exist far more abundantly in human APP
(13 additional such sites were identified, but not shown
in Figure 6A), leading one to speculate that protein
complexes capable of binding to these sites might have
evolved to accommodate the single end-nucleotide
change. The ChIP experiments using H3K9Ac anti-
bodies to immunoprecipitate actively transcribing
chromosomal regions in the undifferentiated SHSY5Y
human cell line identifies the cluster of four E4BP4
binding sites in intron 4 as active compared to three
other regions in the same gene used as negative controls
(shown in Figure 6 panels B and C). These negative con-
trols are introns 15.1, 15.2 and 18 within the same APP
gene. It appears likely therefore that E4BP4/ NFIL3 also
regulates human APP.Variation in levels of β-amyloid in mice brains follows a
circadian pattern
The 42-amino acid β-amyloid peptide levels in brain inter-
stitial fluid of mice have been reported to correlate directly
with wakefulness [43]. Although the study did not find a
similar correlation of full length APP in total tissue homo-
genates, it is intriguing that expression of the transcriptionfactor E4BP4 shown here to regulate appb/ APP expres-
sion follows circadian rhythm controls [35].
Extrapolating results from zebrafish to the human to
formulate hypothesis
Identifying gene regulatory DNA domains with con-
served function but without conserved sequence across
species is a daunting task, especially when they are
located differently in the gene region as noted here be-
tween appb and APP. We propose that regulation of the
APP gene in humans occurs by a mechanism similar to
that of the appb gene in zebrafish, using a similar set of
transcription factors that bind to sites distributed differ-
ently across the gene in the two species. The zebrafish
system allowed rapid identification of important gene-
regulatory sequences through mutational analyses. The
system also helped delineate between several candidate
transcription factor proteins that could potentially bind
to the same DNA sequence. A database search for pro-
teins that contain the conserved DNA-binding domain
of the Forkhead gene family of transcription factors
identified several other DNA-binding proteins. Our abil-
ity to focus on the Forkhead family of proteins arose
from the previous finding in zebrafish that members of
the family fkd1, fkd2 and fkd4 are expressed during gas-
trulation, with high levels of fkd1 and fkd4 mRNA accu-
mulating exclusively in the notochord during
somitogenesis [33].
Conclusion
Here we have functionally analyzed mutations in the two
discontinuous DNA domains in zebrafish appb that were
shown earlier to be important for expression of the gene
in neurons. Previously known transcription factor
E4BP4/ NFIL3 and Forkhead binding sites are shown to
be required for intron 1 enhancer function. Dependence
of neuron specific expression on sequences 31 kb up-
stream of appb is shown to reside in a cluster of three
E4BP4 sites. Both E4BP4/ NFIL3 and Forkhead sites in
these regulatory domains bind the corresponding zebra-
fish proteins efficiently and selectively in vitro. These
sites exist in non-coding DNA of both the zebrafish and
human APP genes at levels much above statistical fre-
quency. Furthermore, a cluster of four E4BP4 sites in in-
tron 4 of human APP is shown to be epigenetically
marked with H3K9Ac in a human neuroblastoma cell-
line that expresses APP. Taken together these findings
suggest that appb in zebrafish and APP in humans may
follow the same regulatory logic using the same set of
transcription factors despite a lack of sequence similarity
in their regulatory DNA. It suggests potential human
APP gene regulatory pathways, not on the basis of com-
paring DNA primary sequences with zebrafish appb but
on the model of conservation of transcription factors.
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Additional file 1: Figure S1. The E. coli expressed DNA-binding protein
domain common to members within gene family, shown in green (A)
E4BP4/ NFIL3, or red (B) Fkd. The corresponding DNA sequence that was
amplified using the PCR primers is underlined.
Additional file 2: Figure S2. Sequences of primers, analyzed using
pDRWN32 software, used to probe chromatin immune-precipitates with
H3K9Ac or control IgG antibody.
Additional file 3: Figure S3. Sequences of primers used to detect
E4BP4/ NFIL3 mRNA levels in the human cell line SHSY5Y using RT-PCR.
Additional file 4: Figure S4. Sequence of intron 1 enhancer is
indicated in black letters, and the sequences of predicted transcription
factor (TF) binding sites indicated in colored letters. The long arrows
indicate the location and directionality of PCR primers used to delete
specific transcription factor binding sites. The thick short underlines
within the SOX5 site indicate point mutations introduced that leave the
overlapping E4BP4 site intact.
Additional 5: Figure S5. Locations of putative binding sites of E4BP4
and XFD1 in zebrafish appb (from Figure 4) and human APP (from
Figure 6A) are tabulated in the top and bottom panels respectively.
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